Bioequivalence of twice-daily oral tacrolimus in transplant recipients: More evidence for consensus?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29135980.
- Also identified by DOI 10.1371/journal.pmed.1002429 and PMC identifier 5685474.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this Perspective on the clinical trial by Rita Alloway and colleagues, Simon Ball explains the benefits to healthcare systems and individual patients of the bioequivalence established between generic and brand-name formulations of an immunosuppressive drug in transplant recipients.
Medical subject headings
- Tacrolimus
- Therapeutic Equivalency